Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Vaccines and breast cancer

Bookmark and Share

11th Milan Breast Cancer Conference 2009

17 - 19 Jun 2009
Published: 28 Nov 2008
Views: 14944
Rating:
Save
Dr Curigliano
From the Milan Breast Cancer Conference

Related Videos

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC
Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Ant...
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC ( Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
13 Jan 2023
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable a...
Dr Ian Krop - Yale Cancer Center, Connecticut, USA
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )
23 Dec 2022
A genomic assay may predict long-term prognosis in premenopausal patients with H...
Dr Ruth O'Regan - University of Rochester, Rochester, USA
A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer ( Dr Ruth O'Regan - University of Rochester, Rochester, USA )
19 Dec 2022
Opinion: Premature regular approval by the FDA
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Opinion: Premature regular approval by the FDA ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
13 Dec 2022
Complex technologies for advanced diagnosis and precision medicine in oncology
Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain
Complex technologies for advanced diagnosis and precision medicine in oncology ( Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain )
24 Oct 2022
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced br...
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
21 Sep 2022
HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan
Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, US...
HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Sep 2022
Lasofoxifene shows promise for women with ESR1-mutated mBC
Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Franc...
Lasofoxifene shows promise for women with ESR1-mutated mBC ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )
11 Sep 2022
Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
19 Jul 2022

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation